Hanmi sets eyes on European markets

Published: 2010-12-02 06:56:00

Updated: 2010-12-02 06:56:00

Hanmi Pharmaceutical Co. is going all-out to make inroads into European countries as its clopidogrel drug has been recently approved by the Medicines Healthcare products Regulatory Agency (MHRA) in UK.

“We will ramp up our overseas expansion drive, with the aim of becoming a global pharmaceuti...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK